News

Month Year

Month Year

Jun 14, 2022

Sanofi Canada furthers commitment to Canadians living with diabetes through mental health resources provided by MindBeacon
May 10, 2022

Sanofi Biogenius Canada Competition returns to Canada-Wide Science Fair
May 3, 2022

Sanofi achieves the third year of Gold-level Gender Parity Certification
Mar 28, 2022

Dupixent® (dupilumab injection) now approved in Canada for the treatment of severe asthma in children aged six to 11 years with type 2 inflammation
Mar 25, 2022

Libtayo® (cemiplimab) now approved in Canada for the treatment of recurrent or metastatic cervical cancer
Jan 25, 2022

Sanofi Canada named one of Forbes Canada's Best Employers for 2022
Dec 9, 2021

Sanofi Canada supports Canada's Walk of Fame in its induction of Frederick Banting, Charles Best, James Collip and John Macleod in the 100th anniversary year of their discovery of insulin
Nov 15, 2021

Nexviazyme™ (avalglucosidase alfa for injection) is now approved in Canada for patients with late-onset Pompe disease (acid α-glucosidase deficiency)
Nov 10, 2021

Canadians living with diabetes want increased mental health resources, are interested in taking a 360-approach towards holistic car
Oct 29, 2021

Libtayo® (cemiplimab) approved in Canada for locally advanced basal cell carcinoma (BCC) patients

Show per page